
Treating Alzheimer’s Agitation, Not Just Quieting It with Pierre N. Tariot, MD
Notas del episodio
In this episode of The JCP Podcast, host Dr. Ben Everett speaks with Dr. Pierre N. Tariot, director of the Banner Alzheimer’s Institute and research professor of psychiatry at the University of Arizona College of Medicine. Dr. Tariot, who has studied agitation and dementia for nearly four decades, chaired an expert consensus panel behind a new report on recognizing, assessing, and treating agitation in Alzheimer’s disease, published in The Primary Care Companion for CNS Disorders.
With most people living with dementia managed in primary care and long waits to see dementia specialists, the panel’s central message is that the goal is not a quieter patient but a safer, more engaged one. Dr. Tariot reviews decades of trial data on carbamazepine, divalproex, atypical antipsychotics, quetiapine, and trazodone, and explains why sedation should not be mistaken for efficacy. The conversation covers ruling out reversible causes, nonpharmacologic approaches including the DICE framework, practical assessment tools, the two FDA-approved therapies, brexpiprazole and dextromethorphan-bupropion, cross-tapering from off-label agents, and emerging treatments on the horizon.
🎯 KEY EPISODE HIGHLIGHTS:
🪞 THE INTRUDER IN THE MIRROR [21:30]
“She saw herself in the mirror when she went into her room and thought that image was an intruder and that she needed to defend herself.”
A home-visit case shows how a careful look at the environment can resolve nightly agitation without any medication at all.
🗣️ AGITATION AS COMMUNICATION [22:36]
“They're communicating that their needs are not being met.”
Reframing disruptive behavior as an expression of unmet needs guides clinicians toward pain, sensory deficits, and other treatable contributors before reaching for a prescription.
🤝 THE MOST ESSENTIAL ELEMENT [37:30]
“If I were to identify the most essential element for therapeutic success, is the willingness of the medical practitioner to engage with the patient and family on this.”
Sustained clinician engagement lowers family anxiety, builds tolerance for setbacks, and anchors a target-symptom approach to treatment over time.
CHAPTERS:
00:00 – Introduction and Dr. Tariot’s Path Into Agitation Research
04:31 – Why This Consensus Report Was Written for Primary Care
07:15 – Four Decades of Trials: Carbamazepine, Divalproex, and the Atypicals
12:17 – Primary Care as the Front Line: Lessons From Depression
16:08 – Sedation Is Not Efficacy
19:33 – Talking With Care Partners and Identifying Unmet Needs
23:52 – Revisiting the Evidence for Quetiapine and Trazodone
28:09 – Two FDA-Approved Options: Brexpiprazole and Dextromethorphan-Bupropion
32:09 – Older Versus Newer Agents and the Boxed Warning
35:03 – Preparing Patients and Families for the Primary Care Visit
40:20 – Measuring Agitation: IPA Criteria, DICE, and Practical Assessment Tools
45:00 – Switching From Off-Label Agents: Cross-Tapering and Practical Barriers
48:30 – What’s Next: Novel Mechanisms, Disease Modification, and One Takeaway
LINKS:
Full transcript and show notes:
The Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Targeted Treatment of Agitation in Alzheimer’s Dementia: Prioritizing Function and Safety Over Sedation and Other Serious Harms
https://www.psychiatrist.com/pcc/targeted-treatment-agitation-alzheimers-dementia/
The consensus panel report chaired by Dr. Tariot, published in The Primary Care Companion for CNS Disorders.
Dr. Pierre N. Tariot – LinkedIn
https://www.linkedin.com/in/pierre-tariot-13557ba/
The Primary Care Companion for CNS Disorders
https://www.psychiatrist.com/pcc/
#AlzheimersDisease #AgitationInDementia #PrimaryCare #GeriatricPsychiatry #Psychopharmacology
Todos los episodios de The Journal of Clinical Psychiatry Podcast